09/03/2019 | |
 | Cancer immunotherapy has emerged as a powerful tool in cancer treatment. The key insight was that a patient’s own immune system could be harnessed to recognize and destroy cancer cells. Allen joined a phase 1 trial at the NIH Clinical Center, one of several sites testing a combination of rituximab (Rituxan) with Hu5F9-G4, a monoclonal antibody that blocks the CD47 protein on tumor cells. This treatment exposes tumor cells to destruction by the immune system. |
No hay comentarios:
Publicar un comentario